Plant Name: Coussarea paniculata
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; | |
| TSHR; | |
| PTPN1; PTPN2; ACP1; PTPRF; CDC25B; | |
| PLA2G1B; RECQL; HSD11B1; AKR1B10; POLB; | |
| MAPK1; EGFR; | |
| CA2; CA1; CA12; CA9; CA7; CA3; CA14; CA5B; CA5A; CA6; | |
| RORC; | |
| THRB; | |
| NR1H4; | |
| KDM4E; | |
| LMNA; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Nuclear hormone receptor subfamily 1 group A | THRB | Thyroid hormone receptor beta-1 | P10828 | CHEMBL1947 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
| Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.009E-13 | 2.745E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.321E-11 | 2.614E-08 | CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.501E-11 | 6.353E-08 | CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.089E-10 | 3.033E-07 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.353E-10 | 4.563E-07 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 5.507E-10 | 6.661E-07 | AKR1B10, CYP1A2, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4, HSD11B1, NR1H4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.113E-09 | 1.054E-06 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9, NR1H4, PTPN1, RORC, THRB |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.500E-09 | 1.361E-06 | CYP1A2, CYP2A13, CYP2C19, CYP2C9, CYP2D6, CYP3A4, RORC |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.384E-09 | 2.834E-06 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.975E-09 | 4.013E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.600E-08 | 1.056E-05 | CYP1A2, CYP2A13, CYP2A6, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 2.375E-08 | 1.327E-05 | CYP1A2, CYP2C9, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 2.376E-08 | 1.327E-05 | CYP2A13, CYP2A6, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 8.771E-08 | 4.341E-05 | CYP1A2, CYP2A13, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 2.070E-07 | 9.591E-05 | CYP2A13, CYP2A6, CYP2D6 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.070E-07 | 3.079E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0035335; peptidyl-tyrosine dephosphorylation | 1.062E-06 | 4.203E-04 | ACP1, CDC25B, PTPN1, PTPN2, PTPRF |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.816E-25 | 8.310E-21 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 3.377E-06 | 1.226E-03 | CYP2A13, CYP2A6 |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 3.487E-06 | 1.245E-03 | CA2, CA7, EGFR, MAPK1, NR1H4, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 1.012E-05 | 3.148E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.012E-05 | 3.148E-03 | CA2, CA7 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.012E-05 | 3.148E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.012E-05 | 3.148E-03 | GPBAR1, NR1H4 |
| BP | GO:0065007; biological regulation | GO:0032431; activation of phospholipase A2 activity | 2.022E-05 | 5.949E-03 | EGFR, PLA2G1B |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 2.022E-05 | 5.949E-03 | PTPN1, PTPN2 |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 2.578E-05 | 7.456E-03 | CYP1A2, EGFR, MAPK1 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 3.043E-19 | 3.313E-15 | CA1, CA12, CA14, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.320E-18 | 3.623E-14 | CA1, CA12, CA2, CA3, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.741E-24 | 2.264E-22 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA7; CA6; CA9; CA14 |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 4.930E-11 | 3.204E-09 | HSD11B1; CYP2C9; CYP2A6; CYP2A13; CYP2D6; CYP1A2; CYP3A4 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.137E-10 | 4.928E-09 | HSD11B1; CYP2C9; CYP2A6; CYP2A13; CYP1A2; CYP3A4; CYP2C19 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.424E-09 | 6.302E-08 | CYP2C9; CYP2A6; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 1.628E-09 | 5.292E-08 | CYP2C9; PLA2G1B; CYP1A2; CYP3A4; CYP2C19 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.084E-07 | 4.515E-06 | PTPN1; MAPK1; ACP1; PTPRF; EGFR |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.534E-06 | 1.028E-04 | CYP2C9; CYP2A6; CYP1A2; CYP3A4 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 4.781E-05 | 6.905E-04 | CYP2C9; CYP2D6; MAPK1; CYP2C19 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.883E-04 | 2.225E-03 | CYP2C9; PLA2G1B; CYP2C19 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.544E-04 | 2.007E-03 | HSD11B1; CYP1A2; CYP3A4 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 2.814E-04 | 3.049E-03 | CA2; NR1H4; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 1.351E-03 | 1.254E-02 | HSD11B1; CYP2C9; CYP2A6; AKR1B10; PLA2G1B; CYP1A2; CYP2C19; CYP3A4 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.983E-03 | 1.719E-02 | PTPN1; MAPK1; PTPRF |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 4.564E-03 | 3.123E-02 | MAPK1; EGFR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 6.102E-03 | 3.824E-02 | MAPK1; EGFR |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 3.947E-03 | 2.851E-02 | MAPK1; EGFR |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 2.472E-03 | 2.008E-02 | MAPK1; EGFR |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 7.818E-03 | 4.235E-02 | PLA2G1B; MAPK1; EGFR |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 6.286E-03 | 3.824E-02 | MAPK1; EGFR |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 3.102E-03 | 2.372E-02 | CYP2A6; CYP3A4 |
| hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.075E-03 | 1.075E-02 | MAPK1; EGFR |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 7.241E-03 | 4.093E-02 | MAPK1; EGFR |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.472E-03 | 3.824E-02 | MAPK1; EGFR |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.139E-05 | 5.102E-04 | CYP2A6; CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
| C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2 |
| K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | EGFR |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | EGFR |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypothyroidism | E03 | THRB |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| C00-D49: Neoplasms | Ovarian cancer | C56 | EGFR; EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | THRB |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperthyroidism | E05 | THRB |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Colon cancer | C50 | EGFR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | EGFR; EGFR |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1; THRB |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; CYP2D6 |
| J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | EGFR; EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | High cholesterol levels in blood | E78.0 | THRB |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1; HSD11B1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
| C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
| NA: NA | Edema | NA | CA2 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; EGFR |
| C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1 |
| C00-D49: Neoplasms | Melanoma | C43 | EGFR |
| C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | EGFR; EGFR |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; EGFR; EGFR; EGFR |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Bladder cancer | C67 | EGFR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HSD11B1; HSD11B1 |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9 |
| C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; HSD11B1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | CA1; CA9; MAPK1; EGFR; CDC25B |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; MAPK1; EGFR |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| C00-D49: Neoplasms | Prostate cancer | C61 | EGFR |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | EGFR; EGFR; EGFR |
| C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | CA1; CA1 |
| A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Wound healing | T14.0-T14.1 | THRB |
| C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PLA2G1B |